Vol 21, No 3 (2014)
Original articles
Published online: 2014-06-09

open access

Page views 3976
Article views/downloads 2561
Get Citation

Connect on Social Media

Connect on Social Media

Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD)

Svetlana Apostolovic, Dragana Stanojevic, Mitja Lainscak, Goetz Gelbrich, Ruzica Jankovic-Tomasevic, Milan Pavlovic, Danijela Djordjevic-Radojkovic, Sonja Salinger-Martinovic, Biljana Putnikovic, Slavica Radovanovic, Finn Waagstein, Miloje Tomasevic, Elvis Tahirovic, Simone Inkrot, Lindy Musial-Bright, Hans-Dirk Düngen
DOI: 10.5603/CJ.a2013.0117
Cardiol J 2014;21(3):265-272.


Background: The aim of our study was to examine regional differences in the demographics, etiology, risk factors, comorbidities and treatment of female patients with heart failure (HF) in the Cardiac Insufficiency BI soprolol Study in ELDerly (CIBIS-ELD) clinical trial.

Methods and results: One hundred and fifty-nine female patients from Germany and 169 from Southeastern (SE) Europe (Serbia, Slovenia and Montenegro) were included in this subanalysis of the CIBIS-ELD trial. Women comprised 54% of the study population in Germany and 29% in SE Europe. German patients were significantly older. The leading cause of HF was arterial hypertension in German patients, 71.7% of whom had a preserved ejection fraction. The leading etiology in SE Europe was the coronary artery disease; 67.6% of these patients had a reduced left ventricular ejection fraction (34.64 ± 7.75%). No significant differences were found in the prevalence of traditional cardiovascular risk factors between the two regions (hypertension, diabetes, hypercholesterolemia, smoking and family history of myocardial infarction). Depression, chronic obstructive pulmonary disease and malignancies were the comorbidities that were noted more frequently in the German patients, while the patients from SE Europe had a lower glomerular filtration rate. Compared with the German HF patients, the females in SE Europe received significantly more angiotensin converting enzyme inhibitors, loop diuretics and less frequently angiotensin receptor blockers and mineralocorticoid receptor antagonists.

Conclusions: Significant regional differences were noted in the etiology, comorbidities and treatment of female patients with HF despite similar risk factors. Such differences should be considered in the design and implementation of future clinical trials, especially as women remain underrepresented in large trial populations.